ImmuPharma plc
IMM.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | -£0 | -£0 | -£0 | £0 |
| % Margin | – | – | – | 100% |
| R&D Expenses | £1 | £2 | £2 | £4 |
| G&A Expenses | £1 | £1 | £1 | £1 |
| SG&A Expenses | £1 | £1 | £1 | £2 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £1 |
| Other Operating Expenses | £0 | -£0 | £0 | £1 |
| Operating Expenses | £3 | £3 | £3 | £7 |
| Operating Income | -£2 | -£3 | -£3 | -£7 |
| % Margin | – | – | – | -5,565.7% |
| Other Income/Exp. Net | -£0 | -£0 | -£1 | -£2 |
| Pre-Tax Income | -£3 | -£3 | -£4 | -£9 |
| Tax Expense | -£0 | -£0 | -£1 | -£1 |
| Net Income | -£2 | -£3 | -£4 | -£8 |
| % Margin | – | – | – | -6,906.6% |
| EPS | -0.006 | -0.008 | -0.013 | -0.033 |
| % Growth | 25.9% | 35.7% | 61.2% | – |
| EPS Diluted | -0.006 | -0.008 | -0.013 | -0.033 |
| Weighted Avg Shares Out | 414 | 361 | 303 | 251 |
| Weighted Avg Shares Out Dil | 416 | 362 | 303 | 251 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£3 | -£3 | -£3 | -£9 |
| % Margin | – | – | – | -7,353.6% |